title: Gadofosveset-enhanced magnetic resonance angiography of the thoracic vasculature in the equilibrium phase: feasibility and impact of dose.
abstract: OBJECTIVE
  The objectives of this study were to evaluate the feasibility of gadofosveset-enhanced magnetic resonance angiography (MRA) of the thoracic vasculature in the equilibrium phase and to determine the impact of gadofosveset dose on imaging quality.
  
  
  METHODS
  Thirty healthy volunteers were randomized to receive a dose of 0.03, 0.02, or 0.01 mmol/kg of gadofosveset for MRA at 3 T in the equilibrium phase. Two radiologists assessed the central veins, the pulmonary arteries, and the thoracic aorta. Quantitative assessments were also performed.
  
  
  RESULTS
  At 0.03 and 0.02 mmol/kg, all vessel segments were rated as adequate. At a dose of 0.01 mmol/kg, less than 10% of vascular segments were collectively rated as inadequate. The signal-to-noise ratio and contrast-to-noise ratio were significantly lower in all segments at 0.01 mmol/kg compared with higher doses.
  
  
  CONCLUSIONS
  Gadofosveset-enhanced MRA of the thoracic vessels in the equilibrium phase in healthy volunteers resulted in adequate vessel visualization, even when dose reduction was performed.This trial was registered with clinicaltrials.gov, identifier NCT01431300.
authors.affiliation: From the *Department of Radiology, Duke University Medical Center, Durham, NC; and †Department of Radiology, University Hospital of Basel, Basel, Switzerland.
authors.forename: Charles Y
authors.initials: CY
authors.lastname: Kim
authors.forename: Tobias
authors.initials: T
authors.lastname: Heye
authors.forename: Mustafa R
authors.initials: MR
authors.lastname: Bashir
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Gebhard
authors.forename: Elmar M
authors.initials: EM
authors.lastname: Merkle
mesh_terms: D000293:Adolescent; D000328:Adult; D003287:Contrast Media / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D005260:Female; D005682:Gadolinium / Q000008:administration & dosage*; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D018810:Magnetic Resonance Angiography / Q000379:methods*; D008297:Male; D009942:Organometallic Compounds / Q000008:administration & dosage*; D013902:Radiography, Thoracic / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013909:Thorax / Q000098:blood supply*; D055815:Young Adult
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; D005682:Gadolinium; C109932:gadofosveset trisodium